Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Webinars

Wed
Jan
26
1:00 PM
US Eastern

Sponsored by Invivoscribe

Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing

In this presentation, Siby Sebastian will review and discuss current guidelines in evaluating, interpreting, and reporting somatic hypermutation (SHM) status in chronic lymphocytic leukemia (CLL) with the focus on laboratory experience in utilizing high-throughput/next-generation sequencing methodology for the SHM status assessment.

Learning objectives:

  • Review and discuss the clinical significance of SHM status assessment in CLL.
  • Review and discuss current guidelines in evaluating, interpreting, and reporting SHM status in CLL.
  • Review and discuss laboratory experience in utilization of high-throughput/next-generation sequencing methodology for assessing SHM status in CLL.

Sponsored by

Thu
Jan
27
11:00 AM
US Eastern

Sponsored by Thermo Fisher Scientific

Rapid Next-Generation Sequencing for the Study of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive, heterogeneous disorder involving clonal expansion of progenitor myeloblasts in the bone marrow and peripheral blood. Research over the last decade has uncovered several recurrent somatic mutations associated with the disease biology. Hence, it may be increasingly important for labs to be able to efficiently profile AML samples for a growing number of diverse mutations, spanning single nucleotide variants, indels, tandem duplications, and gene fusions.

During this presentation, Diana Morlote, assistant professor of pathology at the University of Alabama at Birmingham, will discuss the recent implementation of a rapid, automated next-generation sequencing (NGS) assay in her research laboratory for genomic profiling of AML and other related hematological disorders. The data collected from several cases using the Oncomine Myeloid Assay GX v2 by Thermo Fisher Scientific will be presented. Analytical performance will be discussed for various key mutations detected using DNA inputs. Morlote will describe how this solution addresses key challenges with molecular analysis of AML and other related malignancies. This research furthers our understanding of malignant hematological disorders and may lead to better care in the future.

Sponsored by

Tue
Feb
08
1:00 PM
US Eastern

Sponsored by PGDx

Multiomic Analyses and Cancer Therapy Selection

This webinar is part one of the four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which multiomic profiling has identified biomarkers that may or may not aid clinicians in making treatment decisions.

Precision oncology has seen a natural maturation from guiding therapy decisions based only on testing of specific, largely hotspot DNA mutations to testing that integrates assessment of sequence mutations, structural changes (i.e., deletions, amplifications, fusions), RNA, and protein levels. There are also genomic signatures, such as tumor mutation burden (TMB) and microsatellite instability (MSI), that have further clinical implications in a pan-solid tumor setting.

While these multiple layers of biomarker information have the potential to better inform individualized treatment plans and patient outcomes, they have also made it more difficult for oncologists to readily interpret test results and make clinical decisions. Our panel will discuss in detail several clinical cases where multiomic profiling was conducted and used to recommend a course of treatment for patients based on the available data.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Thu
Feb
10
10:00 AM
US Eastern

Sponsored by Qiagen

From Information Overload to Actionable Insights: How a National Cancer Research Center Identifies Meaningful Mutations in Somatic Tumor Testing

Precision medicine is transforming cancer care, with next-generation sequencing (NGS) enabling the simultaneous analysis of multiple genomic alterations with therapeutic implications. However, due to the sporadic nature of somatic cancers and the increasing uptake of NGS testing, the number of detected variants is exponentially growing, challenging labs to confidently identify meaningful mutations that could influence or improve decisions at the point of care. Approximately 50 percent of the oncologists in the United States find NGS results sometimes or often difficult to interpret, while 31 percent of small to medium-sized labs in Europe view a lack of knowledge and exposure to routine analyses and interpretation as the most critical bottleneck in NGS testing [1-2].

In this webinar, Ana Krivokuca will present a real-world use case of how the Institute for Oncology and Radiology of Serbia (IORS), a national cancer research center that provides routine NGS testing for cancer patients, uses the Human Somatic Mutation Database (HSMD) in their NGS testing pipeline to validate, assess, and better understand the clinical significance of detected variants.

A new somatic database from QIAGEN, HSMD combines two decades of expert-curated content with data from over 300,000 real-world clinical oncology cases to provide deep genomic insight into the molecular characterizations of a patient’s tumor. Easy to search with new content added weekly, HSMD enables users to explore key genes or mutations with driving properties or clinical relevance, search for associated treatment options, evaluate secondary findings, and develop customized gene panels.

Attendees will:

  • Learn how IORS uses HSMD to identify actionable variants, analyze complex reports,  evaluate secondary findings, and design custom gene panels.
  • Explore HSMD content and features through a virtual demonstration.
  • Receive a complimentary, five-day trial of HSMD.

Sponsored by

field_file_image_alt_text_value
Fri
Feb
11
3:00 PM
US Eastern

Sponsored by Natera

Know Cancer’s Next Move: How Circulating Tumor DNA May Serve as a Reliable Biomarker to Predict Recurrence and Aid Patient Stratification

Join us as Dr. Adham Jurdi, Dr. Sakti Chakrabarti, and Dr. Gregory Botta take a closer look at provocative new data surrounding circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment to potentially improve patient management. In this roundtable discussion, panelists will discuss common questions physicians face when treating their gastrointestinal cancer patients including:

  • Are clinicopathological features enough to prognosticate recurrence?
  • How can we use ctDNA to catch relapse earlier and potentially improve patient outcomes?
  • What does the recent data tell us about integrating MRD assays into clinical practice?

Sponsored by

Tue
Feb
22
1:00 PM
US Eastern

Sponsored by PGDx

Applying Tumor Homologous Recombination Deficiency in Practice

This webinar is part two of the four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency (HRD).

HRD is known to be a source of risk for heritable malignancies, such as breast and ovarian cancer. Increasing use of genomic sequencing combined with novel clinical development strategies is now expanding the types of cancer that are known to have an HRD subset and may respond to certain treatment regimens. 

Recently, oral PARP inhibitors have been approved, with the greatest activity observed in patients with HRD tumors. While a family of genes implicated in homologous recombination repair (HRR) have been associated with HRD (and related risk of malignancy), the impact of these genes on the activity of PARP inhibitors is still under study. This has increased the clinical challenges for interpretation of next-generation sequencing HRD results for many oncologists, as they try to keep up with which genes to act upon, when to refer a patient for genetic counseling, and how to prioritize HRD-associated therapy with other treatments that may be options based on a patient’s comprehensive genomic profile.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Thu
Feb
24
1:00 PM
US Eastern

Sponsored by Thermo Fisher Scientific

Application of Chromosomal Microarray Analysis in Oncology

Chromosomal microarray analysis (CMA) is a first-tier molecular cytogenetics test in the constitutional field helping to identify genetic causes of developmental delay, autistic spectrum disorders, or intellectual disability. CMA also plays a significant role in oncology where whole-genome sequencing or whole-exome sequencing are not yet offered as routine tests or when next-generation sequencing (NGS) panels and cytogenetics provide limited or inconclusive results.

In this webinar, Madina Sukhanova, assistant professor of pathology at Northwestern University Feinberg School of Medicine, will discuss the importance of CMA in oncology testing through a series of representative cases. These illustrative cases will demonstrate the utility of CMA combined with NGS assays to identify genetic aberrations associated with specific prognoses in different types of cancer.

Learning objectives:

  • Learn how to investigate interesting oncology cases and findings.
  • Gain a working knowledge of the importance of CMA and how it plays a vital role in oncology testing.
  • Discover the utility of CMA combined with NGS.

Sponsored by

Tue
Mar
08
1:00 PM
US Eastern

Sponsored by PGDx

Impact of Structural Variants and Co-Occurring Variants on Cancer Therapy Prioritization

This webinar is part three of the four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified structural variants with possible clinical relevance.

Improvements in nucleic acid sequencing technology have made the routine detection of structural alterations such as gene fusions, amplifications, and genomic instability signatures possible. In particular, the clinical relevance of gene fusions has expanded, resulting in both FDA-approved and clinically supported treatment options. Additionally, the increased utilization of comprehensive genomic analyses has the potential to inform a broad range of co-occurring somatic and germline alterations that may be associated with hereditary disease, therapeutic selection, and resistance to treatments.

However, this technological progress has increased clinical challenges for oncologists, as they try to keep up with therapeutic opportunities and understand how to prioritize treatment options amid other biomarker-informed therapies that could also potentially benefit patients based on their comprehensive genomic profiling results.

Our panel will address these challenges and opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx
Tue
Mar
22
1:00 PM
US Eastern

Sponsored by PGDx

Therapeutic Options from RAS/MEK Pathway Alterations

This webinar is part four of our four part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified activating mutations in the RAS or MEK pathways.

Molecular alterations in growth factor cell signaling pathways have been observed for most cancers and have led to novel treatment strategies. These pathways are often influenced by activating mutations in the RAS family and/or MEK-mediated signaling. There are now inhibitors of MEK and RAS family members (including the KRAS G12C mutation) with emerging clinical treatment strategies using novel combinations.

Clinical challenges for oncologists related to interpretation of these findings have increased as they try to keep up with the therapeutic options, specifically, when to apply them, and how to prioritize RAS/MEK related genes in the context of other alterations that are revealed in patients' comprehensive genomic profiling reports.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Sponsored by

PGDx